Hepion Pharmaceuticals, Inc. (CTRVP): Entry into a Material Definitive Agreement
Hepion Pharmaceuticals, Inc. (CTRVP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 3, 2026, Hepion Pharmaceuticals, Inc. (the “Company”) entered into a convertible note purchase agreement (the “Agreement”) with Gravitas Capital LP (“Gravitas”) pursuant to which the Company issued a $500,000 secu
How this was made
The 30-second read
Why it matters
The $500k note adds secured debt and warrants, modestly increasing share count if exercised.
Market read
The filing is a routine financing event with limited trading relevance.
What to watch
Potential future conversion at $0.04 could be attractive if the share price rises above that level.
Background
Hepion Pharmaceuticals is a micro‑cap biotech that regularly raises capital via convertible notes.
Ticker impact
Hepion filed an 8‑K reporting a $500,000 secured convertible note and warrant issuance to Gravitas Capital.
minimal impact; price likely to stay flat or see slight uptick on the news.
The amount is modest for a public filing and the terms are standard; no immediate catalyst for large price movement.
Market effects
Limited; primarily affects niche biotech financing trends.
None; the filing is company‑specific.
Low; no broader market effect.
Counterpoint
If the note converts, dilution could pressure the stock, offering a short opportunity.
Key entities
- InvestorGravitas Capital LP
Counterparty receiving the convertible note and warrant.
